Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer

被引：2
|
作者：
Guarneri, V.
Frassoldati, A.
Piacentini, F.
Cagossi, K.
Cavanna, L.
Michelotti, A.
Jovic, G.
Giovannelli, S.
Ficarra, G.
Oliva, C.
Conte, P.
机构：
[1] Univ Modena & Reggio Emilia, Dept Oncol & Hematol, Modena, Italy
[2] Ramazzini Hosp, Div Med Oncol, Carpi, Italy
[3] Hosp Piacenza, Div Med Oncol, Piacenza, Italy
[4] S Chiara Univ Hosp, Div Med Oncol, Pisa, Italy
[5] Univ Modena & Reggio Emilia, Dept Pathol, Modena, Italy
[6] GlaxoSmithKline Inc, Oncol Med Dev Ctr, Greenford, Middx, England
来源：
BREAST CANCER RESEARCH | 2007年 / 9卷 / 01期
关键词：
Breast Cancer; Breast Cancer; Paclitaxel; Trastuzumab; Epirubicin;
D O I：
10.1186/bcr1729
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
    V Guarneri
    A Frassoldati
    F Piacentini
    K Cagossi
    L Cavanna
    A Michelotti
    G Jovic
    S Giovannelli
    G Ficarra
    C Oliva
    P Conte
    [J]. Breast Cancer Research, 9
  • [2] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    [J]. CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [3] CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer-Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data
    Guarneri, V.
    Frassoldati, A.
    Cagossi, K.
    Bottini, A.
    Michelotti, A.
    Cavanna, L.
    Jovic, G.
    Piacentini, F.
    Oliva, C.
    Conte, P. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [5] Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial
    Guarneri, V.
    Frassoldati, A.
    Bottini, A.
    Cagossi, K.
    Cavanna, L.
    Ravaioli, A.
    Amadori, D.
    Giardina, G.
    Oliva, C.
    Conte, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer
    Musolino, Antonino
    Guarneri, Valentina
    Naldi, Nadia
    Bortesi, Beatrice
    Boggiani, Daniela
    Sgargi, Paolo
    Generali, Daniele G.
    Piacentini, Federico
    Dieci, Maria V.
    Ambroggi, Massimo
    Cagossi, Katia
    Gianni, Lorenzo
    Sarti, Samanta
    Bisagni, Giancarlo
    Frassoldati, Antonio
    Conte, Pierfranco
    Ardizzoni, Andrea
    [J]. CANCER RESEARCH, 2015, 75
  • [7] Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
    A Musolino
    N Naldi
    M V Dieci
    D Zanoni
    A Rimanti
    D Boggiani
    P Sgargi
    D G Generali
    F Piacentini
    M Ambroggi
    K Cagossi
    L Gianni
    S Sarti
    G Bisagni
    A Ardizzoni
    P F Conte
    V Guarneri
    [J]. The Pharmacogenomics Journal, 2016, 16 : 472 - 477
  • [8] Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
    Musolino, A.
    Naldi, N.
    Dieci, M. V.
    Zanoni, D.
    Rimanti, A.
    Boggiani, D.
    Sgargi, P.
    Generali, D. G.
    Piacentini, F.
    Ambroggi, M.
    Cagossi, K.
    Gianni, L.
    Sarti, S.
    Bisagni, G.
    Ardizzoni, A.
    Conte, P. F.
    Guarneri, V.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (05): : 472 - 477
  • [9] Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
    Takada, Masahiro
    Sugimoto, Masahiro
    Masuda, Norikazu
    Iwata, Hiroji
    Kuroi, Katsumasa
    Yamashiro, Hiroyasu
    Ohno, Shinji
    Ishiguro, Hiroshi
    Inamoto, Takashi
    Toi, Masakazu
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [10] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
    Printz, Carrie
    [J]. CANCER, 2020, 126 (09) : 1827 - 1827
12345